RASSF1A Promoter Hypermethylation Is a Strong Biomarker of Poor Survival in Patients with Salivary Adenoid Cystic Carcinoma in a Chinese Population
Open Access
- 10 October 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e110159
Abstract
In addition to the clinicopathological parameters, molecular biomarkers are becoming increasingly important in the prognostic evaluation of cancer patients. This study aimed to determine the molecular alterations in the RAS association domain family protein1A gene (RASSF1A) in salivary adenoid cystic carcinoma (ACC) and to evaluate the potential of such alterations as prognostic markers. One hundred and sixty-seven ACC tumor tissues and 50 samples of matched normal salivary gland tissues from the same patients were analyzed for RASSF1A promoter methylation status by bisulfite sequencing PCR (BSP) and/or methylation-specific PCR (MSP). Fifty ACC tumor tissues and matched normal salivary gland tissues were analyzed for loss of heterozygosity (LOH) by examining two microsatellite markers (D3S1478, D3S1621) at 3p21. RASSF1A gene mutations were detected by direct sequencing of all six exons in 50 tumor and normal tissue specimens. Over-all, RASSF1A promoter hypermethylation was detected in 35.3% (59/167) of ACC tissues and was associated with histologically solid tumor pattern (P = 0.002) and advanced TNM stage (P = 0.014). RASSF1A LOH was observed in 18.0% (9/50) of cases, and no somatic mutation of RASSF1A was detected in any cases. RASSF1A promoter methylation was associated with the poor over-all survival (Log-rank test, P P P = 0.009) and disease-free survival (P RASSF1A methylation is involved in the development, differentiation and progression of ACC and is a strong independent biomarker of poor survival in ACC patients in a Chinese population.Keywords
This publication has 40 references indexed in Scilit:
- The Prognostic Role of RASSF1A Promoter Methylation in Breast Cancer: A Meta-Analysis of Published DataPLOS ONE, 2012
- Adenoid cystic carcinoma: A rare clinical entity and literature reviewOral Oncology, 2011
- Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patientsBreast Cancer Research and Treatment, 2011
- The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysisCarcinogenesis, 2010
- PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patientsInternational Journal of Cancer, 2010
- Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patientsJournal of Cancer Research and Clinical Oncology, 2009
- The RASSF1A tumor suppressorJournal of Cell Science, 2007
- Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancerBritish Journal of Cancer, 2006
- Methylation of RAS association domain family protein 1A as a biomarker of lung cancerCancer, 2006
- Adenoid cystic carcinoma of the head and neck.Oral Oncology, 2005